Promising breast cancer combo trial halted early
NCT ID NCT06408168
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 24 times
Summary
This study tested whether the drug repotrectinib, alone or with fulvestrant, could control a specific type of advanced breast cancer called invasive lobular carcinoma. It was for people whose cancer had spread and who had already tried hormone therapy with another drug. The trial was stopped early and only enrolled 6 participants, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.